NCT06582017 - Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

August 28, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

May 30, 2028

Conditions

Ovarian CancerPancreas CancerUrothelial CarcinomaRenal Cell CarcinomaHepatocellular CarcinomaGastrointestinal CancerLung CancerProstate CancerBreast Cancer

Interventions

BIOLOGICAL

QXL138AM Injection every 2 weeks by IV Infusion

masked immuno-cytokine comprised of an anti-CD138 IgG1 antibody fused to human interferon alpha 2a

Trial Locations (8)

11967

NOT_YET_RECRUITING

New York Cancer & Blood Specialists, New York

14642

NOT_YET_RECRUITING

University of Rochester - Wilmot Cancer Institute, Rochester

30322

NOT_YET_RECRUITING

Emory University - Winship Cancer Institute, Atlanta

78229

RECRUITING

START San Antonio, San Antonio

80218

NOT_YET_RECRUITING

Sarah Cannon Research Institute - Denver DDU, Denver

90033

NOT_YET_RECRUITING

University of Southern California, Los Angeles

90048

NOT_YET_RECRUITING

Cedars-Sanai Medical Center - Samuel Oschin Comprehensive Cancer, Los Angeles

92663

NOT_YET_RECRUITING

Hoag Memorial Hospital Presbyterian, Newport